Using CRISPR based gene editing and next generation sequencing, our Precision PGx platform is able to discover synthetically lethal relationships between loss of function mutations and pharmacological drug effects. This creates an opportunity to directly identify drug treatments for cancers driven by loss of function mutations.
Through Leapfrog’s unique Precision PGx Platform we are able to evaluate a broad range therapeutic molecules against all significant loss of function mutations. This process allows us to quickly and efficiently identify known therapeutic agents that can be targeted against cancers with particular genetic mutations. Utilizing the existing data relating to these compounds, we can rapidly advance them through pre-clinical validation and into clinical development.
To test the insights generated from our platform, we retrospectively evaluated real world data to determine the performance of approved therapeutics against cancers with a range of genetic mutations. This evaluation consistently confirmed improved clinical efficacy of treatments predicted by our platform to be effective in specific genetically-defined patients.